Clinical Features | GSE32960(train) | GSE36682(test) | P |
---|---|---|---|
OS | Â | Â | Â |
  0 | 117 | 121 | 0.6897 |
  1 | 39 | 35 | |
Metastatic | Â | Â | Â |
  NO | 122 | 124 | 0.8897 |
  YES | 34 | 32 | |
Relapse | Â | Â | Â |
  NO | 132 | 136 | 0.6256 |
  YES | 24 | 20 | |
T Stage | Â | Â | Â |
  T1 | 30 | 36 | 0.7632 |
  T2 | 48 | 41 | |
  T3 | 36 | 35 | |
  T4 | 42 | 44 | |
N Stage | Â | Â | Â |
  N0 | 23 | 21 | 0.7131 |
  N1 | 73 | 75 | |
  N2 | 39 | 33 | |
  N3 | 21 | 27 | |
Stage | Â | Â | Â |
  I | 5 | 7 | 0.8443 |
  II | 45 | 41 | |
  III | 47 | 44 | |
  IV | 59 | 64 | |
Gender | Â | Â | Â |
  Male | 119 | 114 | 0.6025 |
  Female | 37 | 42 | |
Age | Â | Â | Â |
  ≤ 45 | 78 | 70 | 0.2474 |
  >45 | 78 | 86 | |
EBV | Â | Â | Â |
  YES | 150 | 149 | 1 |
  NO | 6 | 7 | |
Radiotherapy interupt | Â | Â | Â |
  NO | 90 | 88 | 0.9089 |
  YES | 66 | 68 | |
Radiotherapy boosting | Â | Â | Â |
  NO | 85 | 78 | 0.4965 |
  YES | 71 | 78 | |
Cocurrent chemotherapy | Â | Â | Â |
  NO | 26 | 18 | 0.2549 |
  YES | 130 | 138 |